Caresyntax
Caresyntax develops an AI-powered surgical intelligence platform. It analyzes operating room data to provide insights and improve surgical outcomes.
Secondary Market Price
Secondary Market Price
How Caresyntax Measures Up
To help you manage your Caresyntax equity, Prospect has run the company through our machine learning model.
Prospect Rating
Exit Risk
Funding Stage
Series C
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Caresyntax's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Caresyntax Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Caresyntax's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Caresyntax develops an AI-powered, vendor-neutral surgical intelligence platform used in operating rooms to analyze data and improve outcomes. The system ingests and processes a wide range of information—including electronic medical records, video, audio, and device data—to generate insights throughout the surgical workflow. These analytics are used for pre-procedure optimization, real-time support during surgery, and post-procedure clinical review. The company's software is currently used in over 4,200 operating rooms globally, supporting more than three million procedures each year. Founded in 2013 by Dennis Kogan and Björn Von Siemens, Caresyntax is headquartered in San Francisco with a significant international office in Berlin, Germany.
The company continues to expand its partnerships and technological capabilities. Recent announcements include collaborations with German hospitals, such as Klinikum Gütersloh and Klinikum Lippe, to integrate its technology for modernizing surgical environments and workflows. Caresyntax is also focused on the development of its Clinical Data-as-a-Service (CDaaS) platform, which is designed to automate the collection of real-world clinical data for medical device companies and researchers. The company's recent activities also indicate a focus on global expansion, with participation in healthcare AI discussions in the Middle East. In September 2024, Caresyntax completed a Series C funding round, raising $80 million.
- Symbiotic Capital
- MTIP AG
- BIONIQ Capital
- PFM Health Sciences
- Pictet Alternative Advisors
- surgical.ai
- BlackRock Innovation Capital
- Aescuvest
- Optum Ventures
- Cure Capital
- Relyens Group
- Vesalius Biocapital
- Lauxera Capital
- Plug & Play Growth Fund
- ProAssurance Corp
- Intel Capital
- Arno Capital
- Rezayat Investments
- IPF Partners
- Norgine Ventures
- Barco
- Co-Founder, CEO Dennis Kogan
- Co-Founder, Chief Strategy Officer Björn von Siemens
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Caresyntax worth joining?
Deciding to join a company like Caresyntax involves evaluating many factors, including the potential value of its equity compensation. Tools like Prospect can help you model the future value of your equity to make a more informed decision.
What should I do with my Caresyntax stock?
Managing private company stock requires a clear strategy to optimize its value and minimize your tax burden. Platforms like Prospect offer personalized strategies and tools to help you decide when to exercise options or sell shares for the best outcome.
Can you sell Caresyntax stock?
As Caresyntax is a private company, you can typically sell shares during specific liquidity events like a tender offer or on a secondary market. Prospect's tools can help you determine how much to sell and which shares are the most tax-optimal to offload during these opportunities.
How can I find the value of my Caresyntax stock?
Valuing private stock can be complex, but you can get an idea from the company's 409A valuation or recent secondary market transactions. For a more sophisticated forecast, Prospect uses predictive models trained on venture capital data to project your equity's future value.
What is Caresyntax's equity worth?
The total worth of Caresyntax's equity is based on its private valuation, which changes with new funding rounds and business performance. To understand what your specific equity stake could be worth, you can use platforms like Prospect to model different growth scenarios.
What is Caresyntax's stock ticker symbol?
Caresyntax does not have a stock ticker symbol because it is a private company. Ticker symbols are only assigned to companies when they become publicly traded on a stock exchange.
Can I buy or sell Caresyntax stock?
Buying or selling stock in a private company like Caresyntax is generally restricted to specific events like tender offers or transactions on secondary markets. These opportunities are not always available and often have specific eligibility requirements for buyers and sellers.
What is the criteria to buy or invest in Caresyntax stock?
Investing in a private company like Caresyntax is typically limited to accredited investors who meet specific income or net worth thresholds, or through venture capital funds. Employees, however, often receive equity as part of their compensation package without needing to meet these criteria.
